Previous 10 | Next 10 |
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announce...
-AGTC executives will address critical success factors in gene therapy manufacturing and the value of the patient perspective in gene therapy development ---- GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq...
AGTC leads the pack among Biogen, JNJ and MeiraGTx in developing gene therapies for certain eye diseases. Cash balance is decent. If successful, AGTC could see some upside from these levels. For further details see: Applied Genetic Technologies: Leader Among Larger Peers...
The following slide deck was published by Applied Genetic Technologies Corporation in conjunction with their 2021 Q2 earnings call. For further details see: Applied Genetic Technologies Corporation 2021 Q2 - Results - Earnings Call Presentation
Artelo Biosciences (ARTL) +63%.China Liberal Education Holdings Limited (CLEU) +59%.Helius Medical Technologies (HSDT) +29%.Denison Mines Corp. (DNN) +26% on $25M bought deal offering.Xeris Pharmaceuticals (XERS) +25% as EC OK's its Ogluo for severe hypoglycaemia.Inovio Pharmaceutic...
Applied Genetic Technologies Corporation (AGTC) Q2 2021 Earnings Conference Call February 11, 2021 08:00 AM ET Company Participants Sue Washer - Chief Executive Officer Mark Shearman - Chief Scientific Officer Bill Sullivan - Chief Financial Officer Conference Call Participants Jim Birchenoug...
Applied Genetic (AGTC): Q4 GAAP EPS of -$0.60 misses by $0.01.As of December 31, 2020, the Company’s cash, cash equivalents and investments totaled $53.1 million. Press Release For further details see: Applied Genetic EPS misses by $0.01
- Company on track to provide multiple data readouts for XLRP and ACHM clinical programs in 2021 and 2022 - - Net proceeds of approximately $69.2 million from a recent public offering provide cash runway into calendar year 2023 - - Company to host conference call and web...
Article reflects Company’s leadership and innovation in scalable, reproducible manufacture of adeno-associated virus (AAV)-based gene therapies GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC),...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announce...
News, Short Squeeze, Breakout and More Instantly...
Applied Genetic Technologies Corporation Company Name:
AGTC Stock Symbol:
NASDAQ Market:
Applied Genetic Technologies Corporation Website:
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has exte...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purcha...